Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

EPILEPSY

Cenobamate for focal seizures — a game changer?

Nature Reviews Neurology volume 16, pages 133–134 (2020)Cite this article

Subjects

In the first published efficacy study of cenobamate for treatment-resistant focal seizures, high doses produced high seizure-free rates, suggesting cenobamate can outperform existing options. A risk of serious rash and low tolerability at higher doses means further safety studies and clinical experience are needed to determine its clinical value.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Krauss, G. L. et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 19, 38–48 (2019).

    Article  Google Scholar 

  2. Kanner, A. M. et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 91, 82–90 (2018).

    Article  CAS  Google Scholar 

  3. Löscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657–678 (2011).

    Article  Google Scholar 

  4. Gazzola, D. M., Balcer, L. J. & French, J. A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48, 1303–1307 (2007).

    Article  CAS  Google Scholar 

  5. Sperling, M., Klein, P. & Kamin, M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial seizures in a large, multicenter, open-label study. AES 2018 Annual Meeting Abstract Database [abstract 1.303] https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500991 (2018).

  6. Eypasch, E., Lefering, R., Kum, C. K. & Troidl, H. Probability of adverse events that have not yet occurred: a statistical reminder. Br. Med. J. 311, 619–620 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NYU Langone School of Medicine, New York, NY, USA

    Jacqueline A. French

Authors
  1. Jacqueline A. French
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacqueline A. French.

Ethics declarations

Competing interests

J.A.F. receives New York University salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Adamas, Aeonian/Aeovian, Anavex, Arvelle Therapeutics, Axovant, Biogen, BioMotiv/Koutif, Blackfynn, Bloom Science, BridgeValley, Cavion, Cerebral Therapeutics, Cerevel, Crossject, CuroNz, Eisai, Engage Therapeutics, Epitel, Fortress Biotech, GW Pharma, Idorsia, Ionis, Lundbeck, Marinus, Neurocrine, Otsuka Pharmaceutical Development, Ovid Therapeutics, Pfizer, Praxis, Redpin Therapeutics, Sage, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB, West Therapeutic Development, Xenon Pharmaceuticals and Zogenix.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

French, J.A. Cenobamate for focal seizures — a game changer?. Nat Rev Neurol 16, 133–134 (2020). https://doi.org/10.1038/s41582-019-0309-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0309-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing